Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

89Bio Inc (ETNB)

89Bio Inc (ETNB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 788,056
  • Shares Outstanding, K 98,384
  • Annual Sales, $ 0 K
  • Annual Income, $ -142,190 K
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.41
Trade ETNB with:

Options Overview Details

View History
  • Implied Volatility 64.44% ( -3.47%)
  • Historical Volatility 68.76%
  • IV Percentile 20%
  • IV Rank 15.65%
  • IV High 221.57% on 09/29/23
  • IV Low 35.28% on 06/07/24
  • Put/Call Vol Ratio 1.67
  • Today's Volume 8
  • Volume Avg (30-Day) 144
  • Put/Call OI Ratio 2.64
  • Today's Open Interest 18,776
  • Open Int (30-Day) 20,210

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.56
  • Number of Estimates 5
  • High Estimate -0.46
  • Low Estimate -0.60
  • Prior Year -0.52
  • Growth Rate Est. (year over year) -7.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.00 +13.00%
on 06/27/24
9.96 -20.58%
on 06/12/24
+0.01 (+0.13%)
since 05/31/24
3-Month
7.00 +13.00%
on 06/27/24
11.17 -29.19%
on 04/04/24
-2.82 (-26.28%)
since 04/01/24
52-Week
6.57 +20.30%
on 10/23/23
19.89 -60.23%
on 07/03/23
-11.04 (-58.26%)
since 06/30/23

Most Recent Stories

More News
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 2.33 (+3.10%)
GLMD : 0.2800 (+1.82%)
VKTX : 57.72 (+8.89%)
ETNB : 7.91 (-1.25%)
IVA : 2.93 (-2.01%)
SGMT : 3.35 (-2.05%)
TERN : 6.76 (-0.73%)
NVO : 145.66 (+2.05%)
IQV : 210.80 (-0.30%)
MDGL : 281.40 (+0.44%)
Why Shares of 89bio Plummeted on Tuesday

So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors.

AKRO : 23.49 (+0.13%)
ETNB : 7.91 (-1.25%)
Why Akero Therapeutics Stock Is Crashing Today

Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).

ETNB : 7.91 (-1.25%)
AKRO : 23.49 (+0.13%)
Stocks Set to Open Lower as Investors Await Key U.S. Inflation Data, Powell Speech

September S&P 500 futures (ESU23) are down -0.12%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.22% this morning as market participants looked ahead to the release of the Fed’s favorite...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
TSLA : 210.06 (+6.16%)
NVDA : 123.12 (-0.34%)
JD : 25.82 (-0.08%)
PDD : 131.84 (-0.83%)
KMX : 71.53 (-2.47%)
DBK.D.DX : 15.362 (+3.50%)
AML.LN : 144.300 (+0.42%)
MLTX : 43.62 (-0.80%)
ETNB : 7.91 (-1.25%)
GOOGL : 182.21 (+0.03%)
3 Biotech Buyout Targets to Watch

The trio all have late-stage therapies with blockbuster potential.

ETNB : 7.91 (-1.25%)
KRTX : 329.83 (+0.03%)
MORF : 32.32 (-5.14%)
Why Shares of 89bio Soared This Week

The company released positive results for its lead therapy.

ETNB : 7.91 (-1.25%)
89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. (NASDAQ: ETNB) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development of

ETNB : 7.91 (-1.25%)
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

   - Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial...

ETNB : 7.91 (-1.25%)
89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, July 05, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the...

ETNB : 7.91 (-1.25%)
89bio, Inc. Announces Upsized Pricing of $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

SAN FRANCISCO, June 29, 2022 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the...

ETNB : 7.91 (-1.25%)

Business Summary

89bio Inc. is clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is being developed for the treatment of nonalcoholic steatohepatitis....

See More

Key Turning Points

3rd Resistance Point 9.06
2nd Resistance Point 8.62
1st Resistance Point 8.32
Last Price 7.91
1st Support Level 7.58
2nd Support Level 7.14
3rd Support Level 6.84

See More

52-Week High 19.89
Fibonacci 61.8% 14.80
Fibonacci 50% 13.23
Fibonacci 38.2% 11.66
Last Price 7.91
52-Week Low 6.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar